The US$243 analyst price target for LGND is 19% less than our estimate of fair value Today we will run through one way of ...

Abcam and the other 17 members of the partnership today launched the IHI project, LIGAND-AI, to advance AI-driven drug discovery through open science.

Here are three standout stocks that should be on your watchlist in 2026, according to Barchart ratings. Each of these three ...

Ligand Pharmaceuticals’ topical skin infection gel Zelsuvmi is changing hands again—sort of. After Ligand last year created Pelthos Therapeutics to support the launch of Zelsuvmi, Pelthos is now ...

As of Tuesday, January 13, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 7.83%, which has investors ...

This is my tenth Ligand (LGND) article, following my most recent 06/2025 "Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward". In Powers Forward, I rated Ligand as a "Buy". It has since ...

The ability to alter proteins to refine control over binding affinity and specificity can create tailored therapeutics with reduced side effects, highly sensitive diagnostic tools, efficient ...

Royalty Aggregators like Royalty Pharma, Ligand, and XOMA are gaining popularity in the biotech industry. These companies buy up royalty rights to pharmaceutical products, providing upfront cash to ...

Ligand Shareholders Received 4.90007 Shares of OABI and 0.75842 OmniAb Earnout Shares for Each Share of LGND Regular-Way Trading of OABI Begins Tomorrow on Nasdaq Under the terms of the Business ...

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating ...